The yield curve is the only economic indicator pointing to a recession, according to Credit Suisse.Marketsread more
Makan Delrahim, the assistant attorney general for the antitrust division, said a large group of bipartisan state attorneys general have spoken to the Justice Department about...Technologyread more
Stocks slipped on Tuesday as investors digested a sharp rebound from a strong sell-off last week.US Marketsread more
These are the stocks posting the largest moves midday.Market Insiderread more
The move comes as Facebook continues to grapple with its privacy practices and lawmakers' scrutiny over how it uses personal data to display ads. But it probably won't have...Technologyread more
For investors still haunted by last week's monster sell-off, the market's comeback is set to last, according to J.P. Morgan's quant guru.Marketsread more
An under-the-radar hedge fund is ruling the industry with a nearly 30% return this year on its long positions, and it's more than doubling its bet on gold.Marketsread more
estimates@ (Adds company comment from conference call, analyst comment, share move, PIX available)
Aug 7 (Reuters) - CVS Health Corp raised its full-year profit forecast and reported higher-than-expected second-quarter results on Wednesday, as increased U.S. prescription drug prices fueled rebates to its pharmacy benefits business.
CVS shares were up 5% at $56.80, while the broader market was down about 1%.
The company, which last year bought health insurer Aetna for $69 billion, raised its full-year adjusted earnings forecast to $6.89 to $7.00 per share, up from $6.75 to $6.90.
Pharmacy benefit manager (PBM) revenue rose 4.2% to $34.84 billion in the quarter, exceeding Wall Street estimates of $34.2 billion compiled by Evercore ISI. But the company said high dispensing rates of cheap generic drugs limited growth.
CVS also said it expects increased competition for its PBM business in 2020.
Revenue of $21.45 billion from its retail drugstore chains, which compete with Walgreens Boots Alliance Inc, was up 3.7% and also edged past analysts' estimates. But CVS said it is seeing less profit per prescription filled.
Walgreens on Tuesday said it planned to close about 200 U.S. stores, months after saying it would do the same in Britain.
CVS is working to bring more health services into its pharmacies and hopes to drive Aetna clients to take advantage of cheaper care for chronic conditions at its in-store clinics - one of the primary advantages of the acquisition.
"We've got a natural hedge in our enterprise, recognizing that we could have a headwind in one area and it's a tailwind in another area, and that provides a point of differentiation," Chief Executive Larry Merlo said on a call with analysts.
The company said it was already seeing increased customer traffic and sales at walk-in clinics and retail stores where it has launched "HealthHub" pilot pharmacies that provide chronic care management for diabetes and other common health problems.
CVS said it planned to expand the pilot project to 50 stores in four metropolitan areas by the end of 2019.
"We still lack clarity on true financial benefit (of HealthHubs), but the approach makes perfect strategic sense," Evercore ISI analyst Ross Muken said. "In general the message was 'we are making progress despite the headwinds swirling around."'
Those headwinds include intensifying political pressure to lower the cost of U.S. healthcare amid legislative proposals that take aim at insurers and PBMs.
The Aetna business reported revenue of $17.4 billion.
Excluding items, CVS earned $1.89 per share, topping analysts' estimates by 20 cents, according to IBES data from Refinitiv. (Reporting by Manas Mishra and Tamara Mathias in Bengaluru; Michael Erman in New York; Editing by Maju Samuel and Bill Berkrot)